The U.S. Senate gave unanimous approval to a bipartisan bill to “cut the red tape” that stalls scientific research into the medical properties of cannabis and cannabidiols.
The measure – which would authorize the U.S. Food and Drug Administration to study cannabis products – now heads to the U.S. House of Representatives for consideration.
The bill was co-sponsored by Iowa Republican Sen. Chuck Grassley and Hawaii Democrat Brian Schatz, who both lauded the bill’s success.
“This bipartisan bill … will empower the FDA to analyze CBD and medical marijuana products in a safe and responsible way so that the American public can decide whether to utilize them in the future based on sound scientific data.”
The Senate measure comes almost a year after the U.S. Drug Enforcement Administration signaled it might ease its restrictions on marijuana research.